208 related articles for article (PubMed ID: 31673516)
1. Pathologic response after modern radiotherapy for non-small cell lung cancer.
Roy SF; Louie AV; Liberman M; Wong P; Bahig H
Transl Lung Cancer Res; 2019 Sep; 8(Suppl 2):S124-S134. PubMed ID: 31673516
[TBL] [Abstract][Full Text] [Related]
2. Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.
Chi A; Wen S; Monga M; Almubarak M; He X; Rojanasakul Y; Tse W; Remick SC
PLoS One; 2016; 11(9):e0162453. PubMed ID: 27611833
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
Phillips I; Sandhu S; Lüchtenborg M; Harden S
Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
[TBL] [Abstract][Full Text] [Related]
4. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
Palma DA; Nguyen TK; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko B; Laba J; Kwan K; Gaede S; Lee T; Ward A; Warner A; Inculet R
JAMA Oncol; 2019 May; 5(5):681-688. PubMed ID: 30789648
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis.
Li M; Yang X; Chen Y; Yang X; Dai X; Sun F; Zhang L; Zhan C; Feng M; Wang Q
Onco Targets Ther; 2017; 10():2885-2892. PubMed ID: 28652770
[TBL] [Abstract][Full Text] [Related]
6. SABR-BRIDGE:
Kidane B; Spicer J; Kim JO; Fiset PO; Abdulkarim B; Malthaner R; Palma D
Front Oncol; 2020; 10():580189. PubMed ID: 33072612
[TBL] [Abstract][Full Text] [Related]
7. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
Mahmood S; Bilal H; Faivre-Finn C; Shah R
Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381
[TBL] [Abstract][Full Text] [Related]
8. The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection.
Snee MP; McParland L; Collinson F; Lowe CM; Striha A; Baldwin DR; Naidu B; Sebag-Montefiore D; Gregory WM; Bestall J; Hewison J; Hinsley S; Franks K
Pilot Feasibility Stud; 2016; 2():5. PubMed ID: 27965826
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic or Conventional Radiation for Early-Stage Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Mutsaers A; Zhang TW; Louie A; Rodrigues G; Palma D; Qu M
Cureus; 2023 Apr; 15(4):e38198. PubMed ID: 37252503
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA;
Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
13. Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR).
Dhaliwal I; Kassirian S; Mitchell MA; Qiabi M; Warner A; Louie AV; Wong HH; McDonald CM; Rajchgot J; Palma DA
BMC Cancer; 2022 Apr; 22(1):468. PubMed ID: 35484614
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol.
Kidane B; Gerard IJ; Spicer J; Kim JO; Fiset PO; Wawryko P; Cecchini MJ; Inculet R; Abdulkarim B; Fortin D; Qiabi M; Qing G; Enns S; Bashir B; Tankel J; Wakeam E; Warner A; Kopek N; Yaremko BP; Rodrigues GB; Laba JM; Qu M; Malthaner RA; Palma DA
Cancer; 2023 Sep; 129(18):2798-2807. PubMed ID: 37221679
[TBL] [Abstract][Full Text] [Related]
15. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly.
Shirvani SM; Jiang J; Chang JY; Welsh J; Likhacheva A; Buchholz TA; Swisher SG; Smith BD
JAMA Surg; 2014 Dec; 149(12):1244-53. PubMed ID: 25321323
[TBL] [Abstract][Full Text] [Related]
16. Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [
Yang DM; Palma DA; Kwan K; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko BP; Laba J; Gaede S; Warner A; Inculet R; Lee TY
Radiat Oncol; 2021 Jan; 16(1):11. PubMed ID: 33441162
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
[TBL] [Abstract][Full Text] [Related]
18. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
19. Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data.
Rusthoven CG; Kavanagh BD; Karam SD
Ann Transl Med; 2015 Jul; 3(11):149. PubMed ID: 26244136
[TBL] [Abstract][Full Text] [Related]
20. A Population-based Study of the Effectiveness of Stereotactic Ablative Radiotherapy Versus Conventional Fractionated Radiotherapy for Clinical Stage I Non-small Cell Lung Cancer Patients.
Tu CY; Hsia TC; Fang HY; Liang JA; Yang ST; Li CC; Chien CR
Radiol Oncol; 2018 Jun; 52(2):181-188. PubMed ID: 30018522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
